Sanofi vaccine for potentially fatal bacterial infection meets Phase II goals

|About: Sanofi (SNY)|By:, SA News Editor

Sanofi's (SNY) vaccine for the prevention of the Clostridium difficile (C. diff) infection (CDI) met its primary objectives in a Phase II trial.

The vaccine generated an immune response against C. diff toxins A and B, the ones that are largely responsible for CDI, which is a bacterial infection that can cause life-threatening gut inflammation and diarrhea.

The results put Sanofi ahead of Pfizer (PFE) and Valneva for preventing CDI.

Sanofi is now enrolling 15,000 participants in 17 countries for a Phase III trial.

Over 336,000 Americans a year become infected with C. difficile, and the infection is becoming ever more prevalent in healthcare facilities, partly due to the overuse of antibiotics. (PR)